MN-CWT
25.4.2022 14:02:06 CEST | Business Wire | Press release
CWT, the Business-to-Business-for-Employees (B2B4E) travel management platform, announces that Michelle McKinney Frymire has decided to step down from her roles at the Company. As part of the Company’s long-term succession planning process, the Board of Directors has appointed President and Chief Commercial Officer Patrick Andersen as its next President and Chief Executive Officer, effective May 1, 2022. He will also serve on the Company’s Board of Directors.
“Leading CWT through such a critical phase in its evolution has been a great honor,” said McKinney Frymire. “We have made substantial achievements during extraordinary times, and I am grateful to our global team and customers for their trust and supportive partnership. Now, with a strong financial foundation in place, CWT is positioned to accelerate its growth plan and I’m pleased to pass the baton to Patrick.”
“We are excited that Patrick will serve as our next CEO, given his outstanding track record as Chief Commercial Officer and 13 years in international leadership roles at CWT. He has deep-rooted relationships with our customers and stakeholders and has demonstrated superb leadership through overseeing our strategic priorities, expanding RoomIt, and launching our groundbreaking myCWT China technology platform,” said Jim Abrahamson, Chair of the CWT Board. “On behalf of the Board and our global colleagues, we thank Michelle for her many contributions since she joined the Company in 2019 and wish her well in her next endeavors.”
“I’m delighted and honored to lead CWT to its next stage of growth,” said Patrick Andersen. “As travel demand increases, CWT is well positioned to invest in and expand its industry leadership and global relationships. Importantly, I’ll continue our commitment to our core values and look forward to working with our Board and the CWT team to enhance our technology, and further strengthen the travel and events services we provide to our customers around the world.”
Prior to his role as President and Chief Commercial Officer, Mr. Andersen served as Chief Strategy Officer and before that President of the Americas. Since joining the Company in 2008, Mr. Andersen has managed and overseen several industry-defining initiatives including the launch of myCWT China, expanding RoomIt by CWT, and developing innovative long-term GDS technology partnership agreements. He has over 30 years’ experience in global travel & logistics, with various international leadership roles at Deutsche Post Worldwide and DHL. Andersen also serves as a Non-Executive Member of the Board at Global Minnesota, and MNSNAP, and is on the Board of Overseers for the Carlson School of Management. He studied management at the London Business School.
About CWT
CWT is a Business-to-Business-for-Employees (B2B4E) travel management platform on whom companies and governments rely on to keep their people connected. Anywhere, anytime, anyhow – across six continents – the company provides their clients and their employees with innovative technology and an efficient, safe, and secure travel experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom